These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer. Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385 [TBL] [Abstract][Full Text] [Related]
9. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056 [TBL] [Abstract][Full Text] [Related]
11. Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array. Broutin S; Commo F; De Koning L; Marty-Prouvost B; Lacroix L; Talbot M; Caillou B; Dubois T; Ryan AJ; Dupuy C; Schlumberger M; Bidart JM Thyroid; 2014 Jan; 24(1):43-51. PubMed ID: 24256343 [TBL] [Abstract][Full Text] [Related]
12. Vandetanib and the management of advanced medullary thyroid cancer. Campbell MJ; Seib CD; Gosnell J Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050 [TBL] [Abstract][Full Text] [Related]
13. Systemic treatment and management approaches for medullary thyroid cancer. Ernani V; Kumar M; Chen AY; Owonikoko TK Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392 [TBL] [Abstract][Full Text] [Related]
14. Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells. Starenki D; Sosonkina N; Hong SK; Lloyd RV; Park JI Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027376 [TBL] [Abstract][Full Text] [Related]
15. Suppression of B-Raf Hong SK; Starenki D; Wu PK; Park JI Cancer Biol Ther; 2017 Feb; 18(2):106-114. PubMed ID: 27786591 [TBL] [Abstract][Full Text] [Related]
16. Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo. Starenki D; Park JI Endocrinol Metab (Seoul); 2015 Dec; 30(4):593-603. PubMed ID: 26485469 [TBL] [Abstract][Full Text] [Related]
17. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914 [No Abstract] [Full Text] [Related]
18. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946 [TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of motesanib in a medullary thyroid cancer model. Coxon A; Bready J; Kaufman S; Estrada J; Osgood T; Canon J; Wang L; Radinsky R; Kendall R; Hughes P; Polverino A J Endocrinol Invest; 2012 Feb; 35(2):181-90. PubMed ID: 21422803 [TBL] [Abstract][Full Text] [Related]
20. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]